Monte Rosa Therapeutics (GLUE) Capital Expenditures Growth (3y) (2023 - 2026)
Monte Rosa Therapeutics (GLUE) Capital Expenditures Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 16.27% |
| 10 | Monte Rosa Therapeutics | 2.28 Bn | 1.60 Bn | - | -33.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.21% |
| Dec 31, 2025 | -26.73% |
| Sep 30, 2025 | -40.03% |
| Jun 30, 2025 | 173.85% |
| Mar 31, 2025 | -27.39% |
| Dec 31, 2024 | -44.17% |
| Sep 30, 2024 | -39.32% |
| Jun 30, 2024 | 62.90% |
| Mar 31, 2024 | -5.53% |
| Dec 31, 2023 | 862.10% |
| Sep 30, 2023 | -162.76% |